H1 Announces Transfer of its Carevoyance Product Line to Definitive Healthcare

January 23, 2024, New York, NY – H1 announced today that after careful consideration and strategic evaluation, it has made the decision to transfer ownership of its Carevoyance product line to Definitive Healthcare, a leading player in the Medical Device sector. This decision comes as part of H1’s ongoing efforts to streamline operations and focus wholeheartedly on core competencies in the clinical trials and medical affairs space.

By transferring Carevoyance, we are enabling Definitive Healthcare to bring their expertise and dedicated focus to further enhance and evolve the product and provide its customers with ongoing value.

This decision allows H1 to concentrate our resources and energy on its primary capabilities, delivering unmatched support to Life Sciences organizations and their efforts to bring cutting-edge medicine to patients around the world faster.

H1 and Definitive Healthcare teams are working closely together to ensure a seamless transition and are confident that this decision will result in a positive impact for the market.

Questions regarding this announcement can be directed to [email protected].